Hypothesis

Age‑related shifts in the gut microbiome alter the cargo of secreted extracellular vesicles (EVs), which travel via the bloodstream to the brain and reprogram microglial epigenetics toward a pro‑inflammatory state. This EV‑mediated signaling constitutes a core mechanistic axis of inflammaging that operates independently of, yet synergizes with, classical cytokine pathways.

Mechanistic Basis

• Gut microbes release EVs enriched in specific microRNAs (e.g., pathobiont‑derived miR‑155‑5p and depleted commensal‑derived miR‑let‑7f).
• These EVs cross the compromised intestinal barrier and reach the cerebral vasculature, where they are taken up by microglia.
• miR‑155‑5p suppresses SHIP1, amplifying PI3K‑Akt‑NFκB signaling, while loss of miR‑let‑7f diminishes repression of NLRP3, together driving sustained microglial activation and IL‑1β production.
• The resulting neuroinflammation feeds back to the gut via vagal efferents, worsening barrier integrity and further skewing microbial EV output—a self‑reinforcing loop.

Testable Predictions

1. Correlation: In aged mice and humans, plasma levels of microbiota‑derived EVs carrying miR‑155‑5p will positively correlate with serum IL‑6/TNFα and inversely correlate with cognitive performance.
2. Causality: Pharmacological inhibition of EV release from gut bacteria (using broad‑spectrum neutral sphingomyelinase inhibitor GW4869 administered orally) will reduce brain microglial activation and improve memory without altering systemic cytokine levels.
3. Sufficiency: Isolating EVs from aged donors and injecting them into young germ‑free mice will recapitulate microglial epigenetic changes (increased H3K27ac at NFκB targets) and induce mild cognitive deficits.
4. Bidirectionality: Inducing microglial activation via intracerebral LPS will increase gut permeability and shift fecal EV composition toward a pathobiont‑enriched profile, confirming the feedback arm.

Experimental Approach

• Sample collection: longitudinal fecal, plasma, and brain tissue from young (3 mo), middle‑aged (12 mo), and aged (24 mo) mice; parallel human cohort (n=150) stratified by age and cognitive score.
• EV characterization: ultracentrifugation + size‑exclusion chromatography; RNA‑seq for miRNA cargo; nanoparticle tracking for concentration.
• Intervention arms: (a) GW4869 chow, (b) EV‑depleted plasma transfusion, (c) young‑donor FMT as positive control.
• Readouts: flow cytometry for microglial CD86/CD206, ELISA for IL‑1β/TNFα, ATAC‑seq for microglial chromatin accessibility, Morris water maze and novel object recognition for cognition.
• Statistical plan: mixed‑effects models to account for repeated measures; mediation analysis to test whether EV miRNA levels mediate the relationship between dysbiosis index and cognitive decline.

Potential Implications

If validated, this hypothesis repositions the gut‑brain axis in aging as a vesicle‑driven epigenetic communication network rather than a simple cytokine cascade. It suggests that targeting microbial EV biogenesis—through diet‑modulated bacterial enzymes, EV‑release inhibitors, or engineered EVs delivering anti‑inflammatory miRNAs—could break the self‑reinforcing loop more precisely than broad immunosuppression or single‑target biologics. Moreover, measuring circulating microbiota‑EV signatures offers a minimally invasive biomarker for early inflammaging risk, enabling personalized timing of microbiome‑focused interventions.